Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

  • Kristian Brock (Contributor)
  • Peter Hillmen (Speaker)
  • Talha Munir (Contributor)
  • Andy Rawstron (Contributor)
  • Samuel Munoz Vicente (Contributor)
  • Yates, F. (Contributor)
  • Rebecca Bishop (Contributor)

Activity: Academic and Industrial eventsConference, workshop or symposium

Period7 Dec 2017
Event titleASH Annual Meeting Abstracts
Event typeConference